Strategic partnerships Leverage 7 Hills Pharma’s clinical-stage immunostimulant platform to co-develop or bundle with immunotherapy developers and vaccine programs, especially those targeting infectious diseases and cancer, to expand reach and accelerate clinical progress.

Fundraising leverage Capitalize on recent $4.7M financing and ongoing SBIR-style grant history to position collaborations with CROs, contract development and manufacturing organizations, and joint ventures that can accelerate manufacturing scale and clinical trials.

Manufacturing readiness Highlight established manufacturing partnerships (Catalent, Lipoid, Eurofins Advinus) as a selling point for scalable formulation and supply continuity, offering potential customers a near-term path to GMP production for trial or early commercial use.

Clinical pipeline synergy Target immuno-oncology and infectious disease programs that could benefit from LFA-1 and VLA-4 activation to enhance vaccines and checkpoint inhibitors; propose collaboration to evaluate 7HP349 as an adjuvant or combination therapy alongside existing therapies.

End-market readiness Position the lead compound’s oral bioavailability and favorable safety profile as a differentiator for partners seeking convenient, patient-friendly immunostimulants to augment vaccines for influenza, COVID-19, TB, Chagas, and cancer vaccines in development.